309 related articles for article (PubMed ID: 6345900)
1. Effects of dialysis prescription on bone and mineral metabolism: the National Cooperative Dialysis Study.
Harter HR; Laird NM; Teehan BP
Kidney Int Suppl; 1983 Apr; (13):S73-9. PubMed ID: 6345900
[No Abstract] [Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Secondary hyperparathyroidism in renal insufficiency. Prevention and therapy].
Malluche HH; Ritz E
MMW Munch Med Wochenschr; 1976 Jan; 118(5):129-30. PubMed ID: 814442
[No Abstract] [Full Text] [Related]
4. Influences of dialysis prescription on electrolyte and acid-base metabolism: the National Cooperative Dialysis Study.
Teehan BP; Laird NM; Harter HR
Kidney Int Suppl; 1983 Apr; (13):S66-72. PubMed ID: 6345899
[No Abstract] [Full Text] [Related]
5. Mineral and bone metabolism in thyroid disease: a review.
Auwerx J; Bouillon R
Q J Med; 1986 Aug; 60(232):737-52. PubMed ID: 3774957
[TBL] [Abstract][Full Text] [Related]
6. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
7. COSMOS Project: Hemodialysis scenario in Europe.
Cannata-Andía JB; Fernández Martín JL
Nefrologia; 2016; 36(4):381-8. PubMed ID: 27117398
[No Abstract] [Full Text] [Related]
8. Effects of calcium and phosphorus on patients maintained on dialysis.
Goldsmith RS; Arnaud CD; Johnson WJ
Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
[No Abstract] [Full Text] [Related]
9. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
Wolf M; Thadhani R
Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
[TBL] [Abstract][Full Text] [Related]
10. [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Clin Calcium; 2005 Sep; 15 Suppl 1():192-9. PubMed ID: 16279024
[No Abstract] [Full Text] [Related]
11. Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.).
Torregrosa JV; Bover J; Cannata Andía J; Lorenzo V; de Francisco AL; Martínez I; Rodríguez Portillo M; Arenas L; González Parra E; Caravaca F; Martín-Malo A; Fernández Giráldez E; Torres A;
Nefrologia; 2011; 31 Suppl 1():3-32. PubMed ID: 21468161
[No Abstract] [Full Text] [Related]
12. [Parathormone as a uremic toxin. Physiopathological bases and general therapeutic guidelines].
Brancaccio D; Galmozzi C; Pizzocaro G
Minerva Med; 1985 Mar; 76(9-10):377-82. PubMed ID: 3982693
[No Abstract] [Full Text] [Related]
13. [Autologous epithelial body transplantation in the surgical treatment of secondary azotemic hyperparathyroidism].
Frei U; Klempa I; Fassbinder W; Koch KM
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1315-9. PubMed ID: 611843
[No Abstract] [Full Text] [Related]
14. Calcium and phosphorus metabolism and bone disease in uremia.
Kleeman CR; Massry SG; Coburn JW; Popovtzer MM
Clin Orthop Relat Res; 1970; 68():210-37. PubMed ID: 4905786
[No Abstract] [Full Text] [Related]
15. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
Kazama JJ
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
[TBL] [Abstract][Full Text] [Related]
16. Uremia. II.
Merrill JP; Hampers CL
N Engl J Med; 1970 Apr; 282(18):1014-21. PubMed ID: 4908226
[No Abstract] [Full Text] [Related]
17. Effect of lowering dialysate calcium on bone and mineral parameters related to adynamic bone disease.
Spasovski G; Vanholder R
Ther Apher Dial; 2007 Dec; 11(6):455-6; author reply 457. PubMed ID: 18028174
[No Abstract] [Full Text] [Related]
18. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
19. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
Yaginuma T; Yamamoto H
Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the plasma ionized calcium and its therapeutic control in patients treated by regular hemodialysis.
Kaye M; Cohen GF; Chatterjee G; Mangel R
Trans Am Soc Artif Intern Organs; 1969; 15():341-6. PubMed ID: 5791407
[No Abstract] [Full Text] [Related]
[Next] [New Search]
